BioCentury | Jan 25, 2020
Company News

Management tracks: Galapagos promotes Manto to CCO; plus Guardant, Horizon, Acceleron, Lilly, Krystal, Kura and more

...hired Chris Chapman as CCO. He was VP and general manager, U.S. prescription business at Galderma Laboratories L.P. BioCentury...
BioCentury | Oct 10, 2019
Company News

Management tracks: Galderma taps new leadership from Shire; plus iOmx, BioSpecifics, Poseida, Kedalion, GenSight, Lyra, Verrica and Mizuho

...Former Shire CEO Flemming Ørnskov will lead newly independent Galderma Laboratories L.P. as CEO. Joining him is fellow...
BioCentury | Oct 7, 2019
Company News

Oct. 7 Company Quick Takes: Editas-MaxCyte, Goldfinch-Takeda, Prometheus-Takeda, DBV and Galderma

...development, regulatory and commercial milestones, plus royalties. FDA approval for Aklief acne cream FDA approved Galderma Laboratories L.P.’s...
...epicutaneously. Jonathan Block, Associate Editor Viaskin Peanut (DBV-712) Editas Medicine Inc. MaxCyte Inc. Takeda Pharmaceutical Co. Ltd. Goldfinch Biopharma Inc. DBV Technologies S.A. Galderma...
BioCentury | Apr 26, 2019
Clinical News

Maruho planning Japanese submission for pruritus therapy

...humanized mAb against IL-31 receptor α for skin diseases from Chugai Pharmaceutical Co. Ltd. (Tokyo:4519). Galderma...
...atopic dermatitis by mid-year (see "Galderma Planning Phase III Program for Atopic Dermatitis Therapy" ). Galderma...
BioCentury | Mar 15, 2019
Clinical News

Galderma planning Phase III program for atopic dermatitis therapy

...start a Phase III program of the humanized mAb against IL-31 receptor α by mid-year. Galderma...
...concomitant topical corticosteroids. Data were presented at the American Academy of Dermatology meeting in Washington. Galderma...
BioCentury | Jan 3, 2019
Company News

Management tracks: Portola, Coherus

...succeeds former CMO James Lee. Brown was head of global pharmaceutical drug development at the Galderma...
BioCentury | May 2, 2018
Distillery Techniques

Drug delivery

...could include using the implants to deliver other immunotherapy agents in models of solid tumors. Galderma...
BioCentury | Jun 22, 2017
Clinical News

FDA approves Ipsen's Dysport for adult lower limb spasticity

...A complex supplied as a lyophilized powder, is approved in more than 80 countries. The Galderma...
...Euronext:IPN; Pink:IPSEY), Boulogne-Billancourt, France Product: Dysport abobotulinumtoxinA ( Azzalure - EU) (formerly Reloxin) Business: Musculoskeletal Julian Zhu abobotulinumtoxinA Azzalure Dysport Galderma...
BioCentury | Dec 30, 2016
Company News

Bioventus, Galderma deal

...financial terms. Galderma S.A. , Lausanne, Switzerland Bioventus Inc. , Durham, N.C. Business: Neurology Shannon Lehnbeuter Durolane Bioventus Inc. Galderma...
BioCentury | Aug 8, 2016
Clinical News

Dysport abobotulinumtoxinA regulatory update

...type A complex supplied as a lyophilized powder is approved in over 80 countries. The Galderma...
Items per page:
1 - 10 of 205
BioCentury | Jan 25, 2020
Company News

Management tracks: Galapagos promotes Manto to CCO; plus Guardant, Horizon, Acceleron, Lilly, Krystal, Kura and more

...hired Chris Chapman as CCO. He was VP and general manager, U.S. prescription business at Galderma Laboratories L.P. BioCentury...
BioCentury | Oct 10, 2019
Company News

Management tracks: Galderma taps new leadership from Shire; plus iOmx, BioSpecifics, Poseida, Kedalion, GenSight, Lyra, Verrica and Mizuho

...Former Shire CEO Flemming Ørnskov will lead newly independent Galderma Laboratories L.P. as CEO. Joining him is fellow...
BioCentury | Oct 7, 2019
Company News

Oct. 7 Company Quick Takes: Editas-MaxCyte, Goldfinch-Takeda, Prometheus-Takeda, DBV and Galderma

...development, regulatory and commercial milestones, plus royalties. FDA approval for Aklief acne cream FDA approved Galderma Laboratories L.P.’s...
...epicutaneously. Jonathan Block, Associate Editor Viaskin Peanut (DBV-712) Editas Medicine Inc. MaxCyte Inc. Takeda Pharmaceutical Co. Ltd. Goldfinch Biopharma Inc. DBV Technologies S.A. Galderma...
BioCentury | Apr 26, 2019
Clinical News

Maruho planning Japanese submission for pruritus therapy

...humanized mAb against IL-31 receptor α for skin diseases from Chugai Pharmaceutical Co. Ltd. (Tokyo:4519). Galderma...
...atopic dermatitis by mid-year (see "Galderma Planning Phase III Program for Atopic Dermatitis Therapy" ). Galderma...
BioCentury | Mar 15, 2019
Clinical News

Galderma planning Phase III program for atopic dermatitis therapy

...start a Phase III program of the humanized mAb against IL-31 receptor α by mid-year. Galderma...
...concomitant topical corticosteroids. Data were presented at the American Academy of Dermatology meeting in Washington. Galderma...
BioCentury | Jan 3, 2019
Company News

Management tracks: Portola, Coherus

...succeeds former CMO James Lee. Brown was head of global pharmaceutical drug development at the Galderma...
BioCentury | May 2, 2018
Distillery Techniques

Drug delivery

...could include using the implants to deliver other immunotherapy agents in models of solid tumors. Galderma...
BioCentury | Jun 22, 2017
Clinical News

FDA approves Ipsen's Dysport for adult lower limb spasticity

...A complex supplied as a lyophilized powder, is approved in more than 80 countries. The Galderma...
...Euronext:IPN; Pink:IPSEY), Boulogne-Billancourt, France Product: Dysport abobotulinumtoxinA ( Azzalure - EU) (formerly Reloxin) Business: Musculoskeletal Julian Zhu abobotulinumtoxinA Azzalure Dysport Galderma...
BioCentury | Dec 30, 2016
Company News

Bioventus, Galderma deal

...financial terms. Galderma S.A. , Lausanne, Switzerland Bioventus Inc. , Durham, N.C. Business: Neurology Shannon Lehnbeuter Durolane Bioventus Inc. Galderma...
BioCentury | Aug 8, 2016
Clinical News

Dysport abobotulinumtoxinA regulatory update

...type A complex supplied as a lyophilized powder is approved in over 80 countries. The Galderma...
Items per page:
1 - 10 of 205